US Senate Probes FDA Bureaucracy vs. Innovation

The Senate Special Committee on Aging’s hearing yesterday examined a source of tension in American health policy under scrutiny this Rare Disease Week: How does a regulator designed to protect patients avoid becoming a barrier preventing access to lifesaving or life-extending treatments?... By: Goodwin